Meningococcal Vaccine Potency via Bactericidal Antibody Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the immunogenicity and potency of meningococcal capsular saccharide vaccines are inadequate, as they often rely on animal testing or physical characterization, which do not meet stringent regulatory requirements and fail to ensure consistent immune response in humans.
Innovation Solution
A method involving the use of bactericidal antibody binding to assess the potency of meningococcal capsular saccharide vaccines by competing with control saccharides, allowing for the measurement of binding and comparison to a reference inhibition curve to determine vaccine potency, thereby avoiding the need for animal testing and ensuring regulatory compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal testing or physical characterization methods are used to assess vaccine potency, then the assessment process is simpler and faster, but the results do not meet regulatory requirements and fail to ensure consistent immune response in humans
Solution Approach 1:
The patent uses bactericidal antibodies as an intermediary to indirectly measure vaccine potency. Instead of directly testing immune response in animals or measuring physical characteristics, the assay employs bactericidal antibodies that specifically bind to capsular saccharides to serve as a mediator that correlates with immunogenicity, thereby providing a regulatory-compliant method that avoids animal testing while ensuring reliable potency assessment
Solution Approach 2:
The patent replaces the mechanical/biological system of animal immune response testing with an in vitro binding assay system. The complex biological process of immunization and immune response measurement in animals is substituted with a controlled in vitro assay measuring bactericidal antibody binding to vaccine components, achieving regulatory compliance while maintaining assessment reliability
2Reliability
If bactericidal antibody binding assays are used to assess vaccine potency, then regulatory requirements are met and immune response consistency is ensured, but the assay procedure becomes more complex
Solution Approach 1:
The patent employs preliminary action by pre-coating assay plates with control saccharides and preparing bactericidal antibodies before the actual potency assessment. This pre-preparation of assay components and establishment of reference inhibition curves in advance simplifies the operational complexity during actual vaccine batch testing, making the process more routine and easier to execute while maintaining regulatory compliance
3Ease of manufacture
If competitive ELISA methods are used to measure capsular polysaccharide amounts, then the measurement is straightforward, but it does not accurately reflect immunogenicity and potency
Solution Approach 1:
The patent changes the measurement parameter from simple capsular polysaccharide quantification to bactericidal antibody binding measurement. By shifting from measuring the physical presence of polysaccharides to measuring the functional interaction between bactericidal antibodies and vaccine components, the assay achieves both regulatory-compliant immunogenicity assessment and maintains operational feasibility through established ELISA methodology
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides an accurate and reliable method to assess vaccine potency, meeting regulatory standards and ensuring consistent immune response, thereby ensuring vaccine efficacy and safety for human administration.
Implementation Method 1
contacting the meningococcal capsular saccharide vaccine with a bactericidal antibody and a control saccharide, wherein the meningococcal capsular saccharide vaccine competes with the control saccharide for binding to the bactericidal antibody
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E~1F
AI summary
The disclosure provides compositions, methods and kits for assessing immunogenicity, potency, or both, of meningococcal capsular saccharide vaccines. The assessment is based upon measurement of binding of a bactericidal antibody to a capsular saccharide component in the vaccine.